1 Department of Dermatovenereology, Göteborg University, Guldhedsgatan 10B, 413 46 Göteborg, Sweden
2 Department of Clinical Virology, Göteborg University, Guldhedsgatan 10B, 413 46 Göteborg, Sweden
3 UPR9021 du CNRS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
Correspondence
Jan-Åke Liljeqvist
jan-ake.liljeqvist{at}microbio.gu.se
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
![]() |
MAIN TEXT |
---|
![]() ![]() ![]() ![]() |
---|
|
In this study, sera were collected from six isolation-proven patients with HSV-1 infection and six patients with HSV-2 infection. One patient was double infected and this sample was included in both groups. The HSV-1 isolates were collected from orolabial lesions and HSV-2 isolates from genital lesions. Serum samples were assayed in a type-specific HSV-1 ELISA using gG-1 as antigen and a type-specific HSV-2 ELISA using mgG-2 as antigen (Svennerholm et al., 1984; Tunbäck et al., 2000
). Results showed that sera from isolation-positive HSV-1 patients were positive in the type-specific HSV-1 ELISA and sera from the HSV-2-positive patients were reactive in the HSV-2 ELISA. Results were verified by immunoblotting. A recombinant truncated gG-1 (kindly provided by Smith-Kline Beecham) and Helix pomatia lectin-purified mgG-2 (Olofsson et al., 1986
) were coupled to epoxy-activated Sepharose (Pharmacia Biotech) and sera were added to the columns in order to achieve purified anti-gG-1 and anti-mgG-2 antibodies (Liljeqvist et al., 1998
; Tunbäck et al., 2000
). Purified anti-gG-1 samples were reactive in the HSV-1 ELISA, but non-reactive in the HSV-2 ELISA and vice versa. The study protocol was approved by the Ethics Committee of the Medical Faculty of Göteborg University.
The immunodominant region of mgG-2 has been mapped to P552E574 (Liljeqvist et al., 1998). The homologous part of the gG-1 sequence (aa E80L93) was also involved in binding for the majority of human-purified anti-gG-1 antibody samples (Tunbäck et al., 2000
) (Fig. 1
). Although these regions are highly similar, purified antibodies from an HSV double-infected patient presented no cross-reactivity. Here, we analysed peptides covering these regions, carrying amino acid substitutions from the corresponding gG sequences. The sequences of the peptides were based on earlier studies using DNA sequencing of the gG-1 and mgG-2 genes of clinical HSV isolates (Liljeqvist et al., 2000
; Rekabdar et al., 2002
). Purified antibodies were added to the gG-1 and mgG-2 peptides and analysed as described earlier (Liljeqvist et al., 1998
). Binding was determined by visual assessment in which the intensity of the spots was scored (+/++/+++).
Purified anti-gG-1 antibodies from the HSV-1-infected patients (Table 1, patients 16) were added to peptides covering the mgG-2 region, containing amino acid substitutions from the gG-1 sequence (modified mgG-2 peptides). A distinct reactivity was seen for all samples to the control gG-1 sequence (peptide 14), but no cross-reactivity was present to the original mgG-2 peptide (peptide 1). It was evident that antibodies exhibited binding when peptides contained histidine and leucine from the gG-1 sequence (peptides 8 and 9) in an otherwise homotypic mgG-2 background. Thus, the type-specific reactivity of anti-gG-1 antibodies was dependent on the two key-residues H92 and L93. Consequently, the other gG-1 type-specific glutamate residues, E80, E81 and E85, were not involved in binding.
|
Purified anti-mgG-2 antibodies from the HSV-2-positive samples (Table 1, patients 1 and 711) were added to modified gG-1 peptides. No cross-reactivity was detected to the original gG-1 sequence (peptide 1), while a clear reactivity was observed to the control mgG-2 peptide (peptide 14). Reactivity was present for all samples, although with variable intensity, when amino acids 92HL93 were both substituted by prolines (peptides 8 and 9) from the mgG-2 sequence, indicating their importance in binding. All samples exhibited a weak binding to modified gG-1 peptides when histidine was exchanged for proline (H92
P, peptides 6, 11 and 12). For two samples (patients 1 and 8), a weak reactivity was seen when E85 from gG-1 was substituted for phenylalanine (F85) from the mgG-2 sequence (peptide 2).
Purified anti-mgG-2 antibodies were added to membranes containing modified mgG-2 peptides. Four of the samples (patients 1, 7, 9 and 10) reacted to the modified mgG-2 sequence, as long as the C-terminal prolines of the peptide were preserved (Table 1, peptides 15). The other two samples (patients 8 and 11) were unable to bind when F565 was substituted for glutamate from the gG-1 sequence, even though the amino acids 572PP573 were present (peptide 2). Samples from all patients showed reactivity when the first of the two C-terminal prolines was preserved (peptides 7, 10 and 13). When the second of the two prolines was present, binding was detected to peptide 6 for samples derived from patients 1, 7 and 9, while no reactivity was seen to peptides 11 and 12, suggesting that the N-terminal 560GP561 residues were required for binding. One sample (patient 1) presented retained reactivity despite the fact that the C-terminal prolines were changed to 92HL93 from the gG-1 sequence, as long as the peptide contained the type-specific mgG-2 residues 560GP561 and F565 (peptide 8). We concluded that the human antibody response to the mgG-2 region seemed to be polyspecific and that all mgG-2 type-specific residues were involved in binding. Earlier studies, employing mAbs against HSV gC-1 and gC-2, showed that the type-specific reactivity was maintained by a single type-specific amino acid (Dolter et al., 1992
; Kimmel et al., 1990
). Here we have presented similar results for the type-specific behaviour of the human polyclonal antibody response to highly similar immunogenic regions of gG-1 and mgG-2.
To explore the possible conformers of the gG-1 and mgG-2 peptides in an aqueous environment, the INSIGHT II software (Accelrys) was used for molecular modelling on a Silicon Graphics workstation as proposed previously (Bartels et al., 1998). Peptides were minimalized for 5000 cycles by the conjugated gradient minimalization process and then subjected to a dynamic energy sampling at 1000 °K using 10 ps of equilibration and 100 ps of dynamics. Four conformers with minimal potential energy were selected and again minimalized by a conjugated gradient for 4000 steps (final derivatives less than 0·01 kcal1 Å1) showing totally different patterns of conformation (Fig. 2
). The gG-1 peptide presented a restricted flexibility over the whole backbone, with the exception of histidine and leucine residues, which were shown to be essential for type-specific antibody recognition. The restricted flexibility is suggested to be due to the extended form induced by the poly-glutamyl N terminus, avoiding contact between the negatively charged residues and favouring contact of these residues with water molecules. In contrast, the mgG-2 peptide showed a high flexibility, which was made possible by the distribution of proline and glycine residues and lack of the poly-glutamyl N terminus present in gG-1.
|
Molecular modelling results allowed interpretation of the experimental data regarding immunological characteristics of the gG-1 and mgG-2 peptides. Recognition and binding of antibodies are favoured by high mobility of the antigen (Westhof et al., 1984). In addition, homopolymers such as poly-L-glutamic acids are not immunogenic (Sela, 1966
). The combination of these properties points towards the flexible histidineleucine C terminus as the only target for antibody recognition and explains loss of binding if one of these amino acids is substituted. It can therefore be suggested that the anti-gG-1 antibody response to this region is monospecific. This is supported by data on reactivity of human anti-gG-1 antibodies, which showed that peptides containing the poly-glutamyl stretch but lacking the histidine and leucine residues were inert (Tunbäck et al., 2000
). Histidine and leucine were therefore considered energetically essential, constituting a key function for binding. The mgG-2 peptide, in contrast, showed great flexibility in water, which opens up the possibility that several epitopic targets are present and explains the heterogeneous response between patients to different amino acid replacements (Table 1
). With the knowledge that short peptides normally do not demonstrate secondary structures in water, no efforts were made to verify the predicted peptide conformations by nuclear magnetic resonance.
In conclusion, here we employed a substitution analysis of similar regions of gG-1 and mgG-2 using a pepscan technique to dissect the molecular basis for the type-specific reactivity of purified human anti-gG-1 and anti-mgG-2 antibodies. The type-specific polyclonal antibody response to the region of high similarity between gG-1 and mgG-2 investigated here is a prerequisite for using the proteins as antigens for serodiagnostic purposes in HSV-1 and HSV-2 infection. Results showed that the maintenance of type specificity was dependent on single or dual type-specific residues having a key function in binding. Molecular modelling data suggested that the experimental results could be explained by differences in flexibility and structure of the gG peptides, resulting in different exposure of key residues utilized for recognition.
![]() |
ACKNOWLEDGEMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|
Ashley, R., Cent, A., Maggs, V., Nahmias, A. & Corey, L. (1991). Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 115, 520526.[Medline]
Bartels, C., Stote, R. H. & Karplus, M. (1998). Characterization of flexible molecules in solution: the RGDW peptide. J Mol Biol 284, 16411660.[CrossRef][Medline]
Dolter, K. E., Goins, W. F., Levine, M. & Glorioso, J. C. (1992). Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C. J Virol 66, 48644873.[Abstract]
Görander, S., Svennerholm, B. & Liljeqvist, J.-Å. (2003). The secreted portion of glycoprotein G of herpes simplex virus type 2 is a novel antigen for type-discriminating serology. J Clin Microbiol 41, 36813686.
Kimmel, K. A., Dolter, K. E., Toth, G. M., Levine, M. & Glorioso, J. (1990). Serologic type conversion of a herpes simplex virus type 1 (HSV-1) to an HSV-2 epitope caused by a single amino acid substitution in glycoprotein C. J Virol 64, 40334036.[Medline]
Laver, W. G., Air, G. M., Webster, R. G. & Smith-Gill, S. J. (1990). Epitopes on protein antigens: misconceptions and realities. Cell 61, 553556.[Medline]
Liljeqvist, J.-Å., Trybala, E., Svennerholm, B., Jeansson, S., Sjögren-Jansson, E. & Bergström, T. (1998). Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies. J Gen Virol 79, 12151224.[Abstract]
Liljeqvist, J.-Å., Svennerholm, B. & Bergström, T. (2000). Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates. J Clin Microbiol 38, 45174522.
Liljeqvist, J.-Å., Trybala, E., Hoebeke, J., Svennerholm, B. & Bergström, T. (2002). Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. J Gen Virol 83, 157165.
McGeoch, D. J., Dolan, A., Donald, S. & Rixon, F. J. (1985). Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J Mol Biol 181, 113.[Medline]
McGeoch, D. J., Moss, H. W. M., McNab, D. & Frame, M. C. (1987). DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons. J Gen Virol 68, 1938.[Abstract]
Olofsson, S., Lundström, M., Marsden, H., Jeansson, S. & Vahlne, A. (1986). Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92K or gG. J Gen Virol 67, 737744.[Abstract]
Rekabdar, E., Tunbäck, P., Liljeqvist, J.-Å., Lindh, M. & Bergström, T. (2002). Dichotomy of glycoprotein G gene in herpes simplex virus type 1 isolates. J Clin Microbiol 40, 32453251.
Sánchez-Martínez, D., Schmid, D. S., Whittington, W., Brown, D., Reeves, W. C., Chatterjee, S., Whitley, R. J. & Pellett, P. E. (1991). Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies. J Infect Dis 164, 11961199.[Medline]
Sela, M. (1966). Immunological studies with synthetic polypeptides. Adv Immunol 5, 29129.[Medline]
Svennerholm, B., Olofsson, S., Jeansson, S., Vahlne, A. & Lycke, E. (1984). Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J Clin Microbiol 19, 235239.[Medline]
Tunbäck, P., Liljeqvist, J.-Å., Lowhagen, G. B. & Bergström, T. (2000). Glycoprotein G of herpes simplex virus type 1: identification of type-specific epitopes by human antibodies. J Gen Virol 81, 10331040.
Westhof, E., Altschuh, D., Moras, D., Bloomer, A. C., Mondragon, A., Klug, A. & Van Regenmortel, M. H. (1984). Correlation between segmental mobility and the location of antigenic determinants in proteins. Nature 311, 123126.[Medline]
Received 1 October 2004;
accepted 3 November 2004.
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
J MED MICROBIOL | ALL SGM JOURNALS |